ClinVar Genomic variation as it relates to human health
NM_000199.5(SGSH):c.1339G>A (p.Glu447Lys)
The aggregate germline classification for this variant, typically for a monogenic or Mendelian disorder as in the ACMG/AMP guidelines, or for response to a drug. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the aggregate classification.
Stars represent the aggregate review status, or the level of review supporting the aggregate germline classification for this VCV record. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. The number of submissions which contribute to this review status is shown in parentheses.
No data submitted for somatic clinical impact
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NM_000199.5(SGSH):c.1339G>A (p.Glu447Lys)
Variation ID: 5114 Accession: VCV000005114.40
- Type and length
-
single nucleotide variant, 1 bp
- Location
-
Cytogenetic: 17q25.3 17: 80210622 (GRCh38) [ NCBI UCSC ] 17: 78184421 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline Dec 6, 2016 Jun 17, 2024 Mar 25, 2024 - HGVS
-
Nucleotide Protein Molecular
consequenceNM_000199.5:c.1339G>A MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
NP_000190.1:p.Glu447Lys missense NM_001352921.3:c.*426G>A 3 prime UTR NM_001352922.2:c.*389G>A 3 prime UTR NR_148201.2:n.1253G>A non-coding transcript variant NC_000017.11:g.80210622C>T NC_000017.10:g.78184421C>T NG_008229.1:g.14779G>A NG_032778.1:g.45631C>T LRG_1330:g.45631C>T P51688:p.Glu447Lys - Protein change
- E447K
- Other names
- -
- Canonical SPDI
- NC_000017.11:80210621:C:T
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
-
Unknown function
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
- -
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
-
Exome Aggregation Consortium (ExAC) 0.00003
The Genome Aggregation Database (gnomAD) 0.00003
Trans-Omics for Precision Medicine (TOPMed) 0.00004
The Genome Aggregation Database (gnomAD), exomes 0.00007
- Links
Genes
Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
---|---|---|---|---|---|---|
HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
SGSH | - | - |
GRCh38 GRCh38 GRCh37 |
996 | 1478 |
Conditions - Germline
Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
---|---|---|---|---|
Pathogenic/Likely pathogenic (10) |
criteria provided, multiple submitters, no conflicts
|
Mar 25, 2024 | RCV000005421.34 | |
Pathogenic (1) |
criteria provided, single submitter
|
Aug 30, 2022 | RCV000624626.12 | |
Pathogenic (2) |
criteria provided, multiple submitters, no conflicts
|
Sep 16, 2022 | RCV000413635.16 |
Submissions - Germline
Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
---|---|---|---|---|---|
Pathogenic
(Aug 17, 2018)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
Eurofins Ntd Llc (ga)
Accession: SCV000203561.7
First in ClinVar: Feb 02, 2015 Last updated: Jan 09, 2017 |
Number of individuals with the variant: 2
Sex: mixed
|
|
Likely pathogenic
(Apr 27, 2017)
|
criteria provided, single submitter
Method: clinical testing
|
Mucopolysaccharidosis, MPS-III-A
Affected status: unknown
Allele origin:
germline
|
Illumina Laboratory Services, Illumina
Accession: SCV000407341.3
First in ClinVar: Dec 06, 2016 Last updated: May 24, 2019 |
Comment:
The SGSH c.1339G>A (p.Glu447Lys) variant has been reported in three studies and is found in a total of five individuals with mucopolysaccharidosis including two in … (more)
The SGSH c.1339G>A (p.Glu447Lys) variant has been reported in three studies and is found in a total of five individuals with mucopolysaccharidosis including two in a homozygous state and three in a compound heterozygous state (including two siblings who carried a canonical splice site (donor) variant on the second allele) (Blanch et al. 1997; Chabas et al. 2001; Shapiro et al. 2016). The p.Glu447Lys variant was absent from 120 control alleles (Blanch et al. 1997) and is reported at a frequency of 0.00002 in the total population of the Exome Aggregation Consortium. Based on the evidence, the p.Glu447Lys variant is classified as likely pathogenic for mucopolysaccharidosis, type III. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. (less)
|
|
Likely pathogenic
(Nov 07, 2021)
|
criteria provided, single submitter
Method: clinical testing
|
Mucopolysaccharidosis, MPS-III-A
Affected status: no
Allele origin:
germline
|
Genome-Nilou Lab
Accession: SCV002045480.1
First in ClinVar: Jan 03, 2022 Last updated: Jan 03, 2022 |
|
|
Pathogenic
(Sep 16, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Not Provided
Affected status: yes
Allele origin:
germline
|
GeneDx
Accession: SCV000491269.5
First in ClinVar: Jan 09, 2017 Last updated: Mar 04, 2023 |
Comment:
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 18254660, … (more)
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 18254660, 21228398, 25807448, 30809705, 11668611, 24347096, 24816101, 19099774, 11343308, 9158154) (less)
|
|
Likely pathogenic
(-)
|
criteria provided, single submitter
Method: clinical testing
|
Mucopolysaccharidosis, MPS-III-A
(Autosomal recessive inheritance)
Affected status: yes
Allele origin:
germline
|
Lifecell International Pvt. Ltd
Accession: SCV003928027.1
First in ClinVar: Jun 03, 2023 Last updated: Jun 03, 2023 |
Comment:
A Homozygote Missense variant c.1339G>A in Exon 8 of the SGSH gene that results in the amino acid substitution p.Glu447Lys was identified. The observed variant … (more)
A Homozygote Missense variant c.1339G>A in Exon 8 of the SGSH gene that results in the amino acid substitution p.Glu447Lys was identified. The observed variant has a maximum allele frequency of 0.00007/0.00003% in gnomAD exomes and genomes, respectively. The severity of the impact of this variant on the protein is medium, based on the effect of the protein and REVEL score . Rare Exome Variant Ensemble Learner (REVEL) is an ensembl method for predicting the pathogenicity of missense variants based on a combination of scores from 13 individual tools: MutPred, FATHMM v2.3, VEST 3.0, PolyPhen-2, SIFT, PROVEAN, MutationAssessor, MutationTaster, LRT, GERP++, SiPhy, phyloP, and phastCons. The REVEL score for an individual missense variant can range from 0 to 1, with higher scores reflecting greater likelihood that the variant is disease-causing. ClinVar has also classified this variant as Pathogenic and LikelyPathogenic (Variant ID: 5114). This variant was reported among patients affected by mucopolysaccharidosis (Zanetti A et al, 2010). Based on the above evidence this variant has been classified as Likely Pathogenic according to the ACMG guidelines. (less)
Ethnicity/Population group: Asian
Geographic origin: India
|
|
Pathogenic
(Jan 21, 2024)
|
criteria provided, single submitter
Method: clinical testing
|
Mucopolysaccharidosis, MPS-III-A
Affected status: unknown
Allele origin:
germline
|
Labcorp Genetics (formerly Invitae), Labcorp
Accession: SCV000815696.7
First in ClinVar: Oct 10, 2018 Last updated: Feb 20, 2024 |
Comment:
This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 447 of the SGSH protein … (more)
This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 447 of the SGSH protein (p.Glu447Lys). This variant is present in population databases (rs104894639, gnomAD 0.04%). This missense change has been observed in individual(s) with mucopolysaccharidosis (MPS) type IIIA (PMID: 9158154, 19099774, 26787381; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 5114). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SGSH protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. (less)
|
|
Pathogenic
(Mar 25, 2024)
|
criteria provided, single submitter
Method: clinical testing
|
Mucopolysaccharidosis, MPS-III-A
Affected status: unknown
Allele origin:
unknown
|
Baylor Genetics
Accession: SCV001520414.2
First in ClinVar: Mar 22, 2021 Last updated: Jun 17, 2024 |
|
|
Likely pathogenic
(Jan 01, 2019)
|
criteria provided, single submitter
Method: literature only
|
Mucopolysaccharidosis, MPS-III-A
Affected status: yes
Allele origin:
germline
|
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, University of Padova
Accession: SCV000929903.1
First in ClinVar: Jul 28, 2019 Last updated: Jul 28, 2019 |
Comment:
PS3: Low in vivo enzymatic activity in homozygotes; PM2: Very low frequency in GnomAD
|
|
Likely pathogenic
(-)
|
criteria provided, single submitter
Method: clinical testing
|
Mucopolysaccharidosis, MPS-III-A
(Autosomal recessive inheritance)
Affected status: yes
Allele origin:
germline
|
Foundation for Research in Genetics and Endocrinology, FRIGE's Institute of Human Genetics
Accession: SCV002822856.1
First in ClinVar: Jan 21, 2023 Last updated: Jan 21, 2023 |
Comment:
The homozygous missense variation in exon 8 of SGSH gene that results in the amino acid substitution to lysine for glutamic acis at codon of … (more)
The homozygous missense variation in exon 8 of SGSH gene that results in the amino acid substitution to lysine for glutamic acis at codon of 447 was detected. The variant c.1339G>A (p.Glu447Lys) has not been reported in 1000 genome and has a MAF of 0.007% in the gnomAD database. The insilico prediction of the variant is dIsease causing by MutationTaster, CADD , PROVEAN and SIFT. (less)
Clinical Features:
Intellectual disability (present) , Global developmental delay (present) , Coarse facial features (present) , Abnormality of the skeletal system (present)
Age: 0-9 years
Sex: male
Method: DNA extracted from blood was used to perform targeted gene capture using a custom smMIP panel. The libraries were sequenced to mean >100-300X coverage on the Illumina MiSeq sequencing platform. The sequences obtained are aligned to the human reference genome (GRCh37) using the BWA program and analyzed using Picard and GATK version 4.1.2 to identify variants relevant to the clinical indication.
|
|
Pathogenic
(Aug 30, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Inborn genetic diseases
Affected status: unknown
Allele origin:
germline
|
Ambry Genetics
Accession: SCV000741896.5
First in ClinVar: Apr 15, 2018 Last updated: May 01, 2024 |
Comment:
The c.1339G>A (p.E447K) alteration is located in exon 8 (coding exon 8) of the SGSH gene. This alteration results from a G to A substitution … (more)
The c.1339G>A (p.E447K) alteration is located in exon 8 (coding exon 8) of the SGSH gene. This alteration results from a G to A substitution at nucleotide position 1339, causing the glutamic acid (E) at amino acid position 447 to be replaced by a lysine (K). Based on data from gnomAD, the A allele has an overall frequency of 0.01% (18/281098) total alleles studied. The highest observed frequency was 0.04% (13/35374) of Latino alleles. This alteration has been detected in the homozygous state and as compound heterozygous with other pathogenic SGSH alterations in multiple unrelated individuals with Sanfilippo syndrome (Chabas, 2001; Matalonga, 2014; Blanch, 1997; Ambry internal data). This amino acid position is highly conserved in available vertebrate species. Based on internal structural analysis, E447K is deleterious and moderately destabilizing to the local structure (Sidhu, 2014). This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. (less)
|
|
Pathogenic
(May 01, 1997)
|
no assertion criteria provided
Method: literature only
|
MUCOPOLYSACCHARIDOSIS, TYPE IIIA
Affected status: not provided
Allele origin:
germline
|
OMIM
Accession: SCV000025603.3
First in ClinVar: Apr 04, 2013 Last updated: Jan 23, 2017 |
Comment on evidence:
In a patient with mucopolysaccharidosis type IIIA (MPS3A; 252900), Blanch et al. (1997) found a G-to-A transition at nucleotide 1351 of the SGSH gene, which … (more)
In a patient with mucopolysaccharidosis type IIIA (MPS3A; 252900), Blanch et al. (1997) found a G-to-A transition at nucleotide 1351 of the SGSH gene, which resulted in a glu447-to-lys (E447K) amino acid substitution. They found this mutation in compound heterozygosity with the R245H mutation (605270.0001). (less)
|
|
Pathogenic
(Mar 18, 2020)
|
no assertion criteria provided
Method: clinical testing
|
Mucopolysaccharidosis type IIIA
Affected status: unknown
Allele origin:
germline
|
Natera, Inc.
Accession: SCV002095108.1
First in ClinVar: Apr 23, 2022 Last updated: Apr 23, 2022 |
|
|
Likely pathogenic
(May 24, 2017)
|
no assertion criteria provided
Method: clinical testing
|
Mucopolysaccharidosis, MPS-III-A
Affected status: unknown
Allele origin:
unknown
|
Counsyl
Accession: SCV000800766.2
First in ClinVar: Jan 23, 2017 Last updated: Aug 14, 2019 |
|
|
click to load more click to collapse |
Germline Functional Evidence
Functional
Help
The functional consequence of the variant, based on experimental evidence and provided by the submitter. consequence |
Method
Help
A brief description of the method used to determine the functional consequence of the variant. A citation for the method is included, when provided by the submitter. |
Result
Help
A brief description of the result of this method for this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting functional evidence for the germline classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
---|---|---|---|---|
Unknown function
|
Foundation for Research in Genetics and Endocrinology, FRIGE's Institute of Human Genetics
Accession: SCV002822856.1
|
|
Citations for germline classification of this variant
HelpTitle | Author | Journal | Year | Link |
---|---|---|---|---|
Molecular diagnosis of patients affected by mucopolysaccharidosis: a multicenter study. | Zanetti A | European journal of pediatrics | 2019 | PMID: 30809705 |
A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA. | Shapiro EG | The Journal of pediatrics | 2016 | PMID: 26787381 |
Structure of sulfamidase provides insight into the molecular pathology of mucopolysaccharidosis IIIA. | Sidhu NS | Acta crystallographica. Section D, Biological crystallography | 2014 | PMID: 24816101 |
Treatment effect of coenzyme Q(10) and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease. | Matalonga L | Journal of inherited metabolic disease | 2014 | PMID: 24347096 |
Carrier testing for severe childhood recessive diseases by next-generation sequencing. | Bell CJ | Science translational medicine | 2011 | PMID: 21228398 |
[Postnatal and prenatal diagnosis of mucopolysaccharidosis type III (Sanfilippo syndrome)]. | Zhang WM | Zhonghua er ke za zhi = Chinese journal of pediatrics | 2008 | PMID: 19099774 |
Mutation and haplotype analyses in 26 Spanish Sanfilippo syndrome type A patients: possible single origin for 1091delC mutation. | Chabás A | American journal of medical genetics | 2001 | PMID: 11343308 |
Molecular defects in Sanfilippo syndrome type A. | Blanch L | Human molecular genetics | 1997 | PMID: 9158154 |
http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=SGSH | - | - | - | - |
Text-mined citations for rs104894639 ...
HelpRecord last updated Nov 10, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.